Q3 2017 Earnings Estimate for Neurocrine Biosciences, Inc. Issued By Leerink Swann (NBIX)
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at Leerink Swann increased their Q3 2017 earnings estimates for Neurocrine Biosciences in a research note issued on Tuesday. Leerink Swann analyst P. Matteis now forecasts that the company will post earnings per share of ($0.50) for the quarter, up from their previous estimate of ($0.51). Leerink Swann currently has a “Outperform” rating and a $72.00 price objective on the stock. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q4 2017 earnings at ($0.40) EPS, FY2017 earnings at ($2.48) EPS and FY2018 earnings at ($2.10) EPS.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The company had revenue of $6.34 million for the quarter, compared to analyst estimates of $0.61 million. During the same period last year, the company posted ($0.46) EPS.
A number of other brokerages also recently weighed in on NBIX. BMO Capital Markets reaffirmed an “outperform” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 5th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 7th. ValuEngine raised shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $68.81.
Neurocrine Biosciences (NASDAQ NBIX) opened at 61.86 on Thursday. Neurocrine Biosciences has a 52-week low of $37.35 and a 52-week high of $63.77. The firm’s market capitalization is $5.46 billion. The company’s 50-day moving average is $58.03 and its 200-day moving average is $51.01.
Institutional investors and hedge funds have recently bought and sold shares of the company. Canada Pension Plan Investment Board raised its position in shares of Neurocrine Biosciences by 49.7% in the 2nd quarter. Canada Pension Plan Investment Board now owns 24,700 shares of the company’s stock worth $1,136,000 after purchasing an additional 8,200 shares during the last quarter. BlackRock Inc. raised its position in shares of Neurocrine Biosciences by 14,216.0% in the 1st quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after purchasing an additional 4,996,784 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Neurocrine Biosciences in the 1st quarter worth about $4,330,000. Schwab Charles Investment Management Inc. raised its position in shares of Neurocrine Biosciences by 8.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 346,906 shares of the company’s stock worth $15,022,000 after purchasing an additional 27,245 shares during the last quarter. Finally, Janus Capital Management LLC raised its position in shares of Neurocrine Biosciences by 85.0% in the 1st quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock worth $188,759,000 after purchasing an additional 2,002,899 shares during the last quarter.
In other news, insider Haig P. Bozigian sold 26,250 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the sale, the insider now owns 144,601 shares in the company, valued at approximately $8,676,060. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Christopher Flint Obrien sold 8,734 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total transaction of $436,700.00. Following the sale, the insider now owns 57,707 shares in the company, valued at approximately $2,885,350. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 132,580 shares of company stock worth $7,440,850. Company insiders own 4.80% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.